The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting is recognised as the premier educational, scientific, research, and networking event in nuclear medicine and molecular imaging. The 2022 Annual Meeting was held as a hybrid event in Vancouver, Canada, from Saturday, June 11 – Tuesday, June 14. The four-day event provided physicians, technologists, pharmacists, laboratory professionals, and scientists with an in-depth view of the latest research and development in the field as well as provided insights into practical applications for the clinic.
Merle Hoenig, Post-Doc at the Institute for Neuroscience and Medicine II at the Research Center Juelich and the Department of Nuclear Medicine in Cologne (Germany), presented an oral talk entitled “Inverse relationship between education and amyloid burden in individuals with subjective cognitive decline plus and mild cognitive impairment”. In this work, Merle used data of 197 people with subjective cognitive decline (SCD), 227 with mild cognitive impairment (MCI) and 157 with Alzheimer’s disease (AD), which were collected as part of the AMYPAD Diagnostic and Patient Management Study (DPMS). She presented results indicating that higher educated individuals with SCD+ may be more susceptible to the effects of amyloid on cognition at subthreshold and early amyloid phases, whereas in clinical AD higher education may be associated with compensatory mechanisms that permit higher tolerance of marked amyloid burden.
Mark your agenda for next year! The SNMMI 2023 Annual Meeting will be held from June 24-27 in Chicago (US).
You can find more about the conference here.
This article was originally posted on: https://amypad.eu/news/recent-news/amypad-presents-at-snmmi-2022/